Should I buy or sell Actinium Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks .

What is Actinium Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued twelve-month price targets for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's stock price to reach $27.15 in the next twelve months. This suggests a possible upside of 549.5% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts .

How have ATNM shares performed in 2023?

Actinium Pharmaceuticals' stock was trading at $10.65 at the start of the year. Since then, ATNM stock has decreased by 60.8% and is now trading at $4.18. View the best growth stocks for 2023 here .

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,850,000 shares, a decrease of 7.5% from the October 31st total of 2,000,000 shares. Based on an average trading volume of 190,100 shares, the days-to-cover ratio is currently 9.7 days. View Actinium Pharmaceuticals' Short Interest .

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?

Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP) , Fitbit (FIT) , Global Ship Lease (GSL) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Gran Tierra Energy (GTE) , Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO) .

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Brandywine Global Investment Management LLC (0.64%), Charles Schwab Investment Management Inc. (0.28%), Invesco Ltd. (0.12%), Deutsche Bank AG (0.06%), Deutsche Bank AG (0.06%) and UBS Group AG (0.04%). View institutional ownership trends .

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Actinium Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ATNM)

$4.18

+0.16 (+3.98%)

(As of 11/29/2023 ET)

Compare

Today's Range: $4.02
▼
$4.25
50-Day Range: $7.12
▼
$14.26
52-Week Range: $4.00
▼
$14.70

Volume: 136,963 shs
Average Volume: 261,712 shs
Market Capitalization: $114.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.15

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Actinium Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 549.5% Upside
$27.15 Price Target
Short Interest: Healthy
6.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.03) to ($1.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.15, Actinium Pharmaceuticals has a forecasted upside of 549.5% from its current price of $4.18.
Amount of Analyst Coverage
Actinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.75% of the outstanding shares of Actinium Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
Change versus previous month
Short interest in Actinium Pharmaceuticals has recently decreased by 7.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Actinium Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Actinium Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATNM.

3.1

News and Social Media Coverage

News Sentiment
Actinium Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
12 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
MarketBeat Follows
5 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 22.38% of the stock of Actinium Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Actinium Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Actinium Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Actinium Pharmaceuticals has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATNM Stock News Headlines

November 27, 2023 | msn.com

Cadila Pharmaceuticals inaugurates Rs 200-crore API plant in Dahej, aims to expand to new markets

November 21, 2023 | americanbankingnews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Sell at StockNews.com

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 6, 2023 | finance.yahoo.com

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

November 5, 2023 | markets.businessinsider.com

Promising Iomab-B Therapy Results and Sound Financial Standing Bolster Buy Rating for Actinium Pharmaceuticals

November 3, 2023 | seekingalpha.com

Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy

November 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), Sotera Health (SHC) and Elevation Oncology (ELEV)

November 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Actinium Pharmaceuticals (ATNM) and QuidelOrtho (QDEL)

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 2, 2023 | finance.yahoo.com

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023

November 2, 2023 | finance.yahoo.com

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial

October 31, 2023 | finance.yahoo.com

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

October 4, 2023 | finance.yahoo.com

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy

October 4, 2023 | msn.com

B. Riley Securities Reiterates Actinium Pharmaceuticals (ATNM) Buy Recommendation

October 3, 2023 | markets.businessinsider.com

Promising Future for Actinium Pharmaceuticals: Potential Acquisition Target and Progress towards Commercialization

September 27, 2023 | finance.yahoo.com

Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting

September 23, 2023 | finance.yahoo.com

Actinium to Host Key Opinion Leader Event Focused on Bone Marrow Transplant, Potential Role of Iomab-B on May 12

September 15, 2023 | msn.com

Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?

September 10, 2023 | msn.com

HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead

September 7, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Inovio Pharmaceuticals (INO)

September 7, 2023 | finance.yahoo.com

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

September 7, 2023 | msn.com

HSBC Initiates Coverage of Actinium Pharmaceuticals (ATNM) with Buy Recommendation

September 1, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)

August 31, 2023 | finance.yahoo.com

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

August 21, 2023 | finance.yahoo.com

Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

August 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Actinium Pharmaceuticals (ATNM) Buy Recommendation

See More Headlines

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:ATNM
Previous Symbol: AMEX:ATNM
CUSIP: N/A
CIK: N/A
Web: www.actiniumpharmaceuticals.com
Phone: (646) 677-3870
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.15
High Stock Price Target: $50.00
Low Stock Price Target: $11.60
Potential Upside/Downside: +549.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,020,000.00
Net Margins: N/A
Pretax Margin: -102,975.55%
Return on Equity: -91.02%
Return on Assets: -49.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.87
Quick Ratio: 9.87

Sales & Book Value

Annual Sales: $1.03 million
Price / Sales: 111.24
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.59 per share
Price / Book: 2.63

Miscellaneous

Outstanding Shares: 27,410,000
Free Float: 26,316,000
Market Cap: $114.57 million
Optionable: Not Optionable
Beta: 0.31

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Sandesh C. Seth M.B.A. (Age 59)
M.S., Chairman & CEO
Comp: $1.15M
Mr. Steven O'Loughlin BS (Age 37)
CFO & Corporate Secretary
Comp: $585k
Dr. Paul Diamond Esq.
Ph.D., Vice President of Patent & Legal Counsel
Dr. David Gould
Senior Vice President of Corporate Development & Corporate Affairs
Dr. Bernie Cunningham P.M.P.
Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project Management
Dr. Qing Liang
VP & Head of Radiation Sciences
Dr. Avinash Desai M.D.
Chief Medical Officer
Ms. Jenny Hsieh
Chief Strategy Officer
Ms. Sunitha Lakshminarayanan
Senior VP, Head of CMC & Product Development
Ms. Elaina Haeuber
VP & Head of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.
What is Actinium Pharmaceuticals' stock price target for 2024?: 4 Wall Street analysts have issued twelve-month price targets for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's stock price to reach $27.15 in the next twelve months. This suggests a possible upside of 549.5% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.
How have ATNM shares performed in 2023?: Actinium Pharmaceuticals' stock was trading at $10.65 at the start of the year. Since then, ATNM stock has decreased by 60.8% and is now trading at $4.18.
View the best growth stocks for 2023 here.
Are investors shorting Actinium Pharmaceuticals?: Actinium Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,850,000 shares, a decrease of 7.5% from the October 31st total of 2,000,000 shares. Based on an average trading volume of 190,100 shares, the days-to-cover ratio is currently 9.7 days.
View Actinium Pharmaceuticals' Short Interest.
How were Actinium Pharmaceuticals' earnings last quarter?: Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?: Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Actinium Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).
Who are Actinium Pharmaceuticals' major shareholders?: Actinium Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Brandywine Global Investment Management LLC (0.64%), Charles Schwab Investment Management Inc. (0.28%), Invesco Ltd. (0.12%), Deutsche Bank AG (0.06%), Deutsche Bank AG (0.06%) and UBS Group AG (0.04%).
View institutional ownership trends.
How do I buy shares of Actinium Pharmaceuticals?: Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ATNM) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial